Related Experiment Video
Updated: Jun 22, 2025
06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
Novel Ultrasound-Responsive Amyloid Formulation
Maytham Ismail1, Mathumai Kanapathipillai1
1Department of Mechanical Engineering, University of Michigan-Dearborn, Dearborn, MI 48128, USA.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2024
Summary
Novel amyloid aggregates from RIP3 peptide and Pluronic F127 show ultrasound-responsive drug delivery for lung cancer. These peptide aggregates efficiently deliver Doxorubicin, enhancing cancer cell toxicity.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Amyloid aggregates are explored for biomedical applications, especially in drug delivery.
- Developing stimuli-responsive drug delivery systems is crucial for targeted therapies.
Purpose of the Study:
- To create novel amyloid aggregates using a RIP3 peptide and Pluronic F127 copolymer.
- To evaluate the physicochemical and ultrasound-responsive properties of these aggregates.
- To assess their potential as a drug depot for lung cancer treatment using Doxorubicin.
Main Methods:
- Synthesis and characterization of RIP3/F127 amyloid aggregates.
- Assessment of physicochemical properties (size, morphology, stimuli-responsiveness).
- In vitro evaluation of drug delivery efficacy and cytotoxicity in lung cancer cells using Doxorubicin.
Main Results:
- RIP3 and RIP3/F127 demonstrated amyloidogenic properties.
- RIP3/F127 aggregates showed significant ultrasound responsiveness.
- Ultrasound-treated RIP3/F127/Doxorubicin formulations enhanced lung cancer cell toxicity compared to Doxorubicin alone.
Conclusions:
- Amyloidogenic peptide aggregates can be engineered with stimuli-responsive properties.
- RIP3/F127 amyloid aggregates serve as efficient drug delivery depots.
- Ultrasound-responsive amyloid aggregates show promise for targeted lung cancer therapy.
